Dendritic cells and cytokines in human inflammatory and autoimmune diseases

Cytokine and Growth Factor Reviews

Volumn 19, Issue 1, 2008, Pages 41-52

  Blanco, Patrick ^a,b,c   Palucka, A Karolina ^d   Pascual, Virginia ^d   Banchereau, Jacques ^d  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b CNRS Bordeaux Segalen University   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

Author keywords

Dendritic cells; IFN ; IL 1; IL 12; IL 23; TNF

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUTOIMMUNE DISEASE; CELL ACTIVATION; CELL FUNCTION; CELL MATURATION; CYTOKINE PRODUCTION; DENDRITIC CELL; HOMEOSTASIS; HUMAN; IMMUNOLOGICAL TOLERANCE; INFLAMMATORY DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION;

EID: 39049088951     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2007.10.004     Document Type: Article

References (157)

1. Germain R.N. An innately interesting decade of research in immunology. Nat Med 10 (2004) 1307-1320
2. Steinman R.M., Hawiger D., and Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 21 (2003) 685-711
3. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6 (2005) 345-352
4. Shevach E.M. Regulatory/suppressor T cells in health and disease. Arthritis Rheum 50 (2004) 2721-2724
5. Tang Q., and Bluestone J.A. Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev 212 (2006) 217-237
6. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
7. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., et al. Immunobiology of dendritic cells. Annu Rev Immunol 18 (2000) 767-811
8. Guermonprez P., Valladeau J., Zitvogel L., Thery C., and Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20 (2002) 621-667
9. Liu Y.J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23 (2005) 275-306
10. Mellman I. Antigen processing and presentation by dendritic cells: cell biological mechanisms. Adv Exp Med Biol 560 (2005) 63-67
11. Shortman K., and Naik S.H. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 7 (2007) 19-30
12. Ueno H, Klechevsky E, Morita R, Aspord C, Cao T, Matsui T, et al. Dendritic cell subsets in health and disease. Immunol Rev 2007;219:118-42.
13. Dittel B.N., Visintin I., Merchant R.M., and Janeway Jr. C.A. Presentation of the self antigen myelin basic protein by dendritic cells leads to experimental autoimmune encephalomyelitis. J Immunol 163 (1999) 32-39
14. Eriksson U., Ricci R., Hunziker L., Kurrer M.O., Oudit G.Y., Watts T.H., et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 9 (2003) 1484-1490
15. Bondanza A., Zimmermann V.S., Dell'Antonio G., Dal Cin E., Capobianco A., Sabbadini M.G., et al. Cutting edge: dissociation between autoimmune response and clinical disease after vaccination with dendritic cells. J Immunol 170 (2003) 24-27
16. Banchereau J., Pascual V., and Palucka A.K. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 20 (2004) 539-550
17. Banchereau J., and Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25 (2006) 383-392
18. Janeway Jr. C.A., Yagi J., Conrad P.J., Katz M.E., Jones B., Vroegop S., et al. T-cell responses to Mls and to bacterial proteins that mimic its behavior. Immunol Rev 107 (1989) 61-88
19. Akira S., Uematsu S., and Takeuchi O. Pathogen recognition and innate immunity. Cell 124 (2006) 783-801
20. Medzhitov R., and Janeway Jr. C.A. Decoding the patterns of self and nonself by the innate immune system. Science 296 (2002) 298-300
21. Figdor C.G., van Kooyk Y., and Adema G.J. C-type lectin receptors on dendritic cells and Langerhans cells. Nat Rev Immunol 2 (2002) 77-84
22. Geijtenbeek T.B., van Vliet S.J., Engering A., 't Hart B.A., and van Kooyk Y. Self- and nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol 22 (2004) 33-54
23. Martinon F., and Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol 26 (2005) 447-454
24. Ting J.P., and Davis B.K. CATERPILLER: a novel gene family important in immunity, cell death, and diseases. Annu Rev Immunol 23 (2005) 387-414
25. Gallucci S., Lolkema M., and Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 5 (1999) 1249-1255
26. Sauter B., Albert M.L., Francisco L., Larsson M., Somersan S., and Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191 (2000) 423-434
27. Seong S.Y., and Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 4 (2004) 469-478
28. Srivastava P.K., and Maki R.G. Stress-induced proteins in immune response to cancer. Curr Top Microbiol Immunol 167 (1991) 109-123
29. Lotze M.T., and Tracey K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5 (2005) 331-342
30. Biragyn A., Ruffini P.A., Leifer C.A., Klyushnenkova E., Shakhov A., Chertov O., et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 298 (2002) 1025-1029
31. Rock K.L., Hearn A., Chen C.J., and Shi Y. Natural endogenous adjuvants. Springer Semin Immunopathol 26 (2005) 231-246
32. Piqueras B., Connolly J., Freitas H., Palucka A.K., and Banchereau J. Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors. Blood 107 (2006) 2613-2618
33. Flynn S., Toellner K.M., Raykundalia C., Goodall M., and Lane P. CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J Exp Med 188 (1998) 297-304
34. Ito T., Yang M., Wang Y.H., Lande R., Gregorio J., Perng O.A., et al. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med 204 (2007) 105-115
35. Grouard G., Rissoan M.C., Filgueira L., Durand I., Banchereau J., and Liu Y.J. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 185 (1997) 1101-1111
36. Siegal F.P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P.A., Shah K., Ho S., et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 284 (1999) 1835-1837
37. Shortman K., and Liu Y.-J. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2 (2002) 151-161
38. Pulendran B., Smith J.L., Jenkins M., Schoenborn M., Maraskovsky E., and Maliszewski C.R. Prevention of peripheral tolerance by a dendritic cell growth factor: Flt3 ligand as an adjuvant. J Exp Med 188 (1998) 2075-2082
39. Dudziak D., Kamphorst A.O., Heidkamp G.F., Buchholz V., Trumpfheller C., Yamazaki S., et al. Differential antigen processing by dendritic cell subsets in vivo. Science 315 (2007) 107-111
40. + T cells to produce IFN-γ by a CD70 dependent, IL-12 independent mechanism. J Exp Med 2007;204:1095-106.
41. Valladeau J., and Saeland S. Cutaneous dendritic cells. Semin Immunol 17 (2005) 273-283
42. Kadowaki N., Ho S., Antonenko S., Malefyt R.W., Kastelein R.A., Bazan F., et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194 (2001) 863-869
43. Jarrossay D., Napolitani G., Colonna M., Sallusto F., and Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 31 (2001) 3388-3393
44. van der Aar A.M., Sylva-Steenland R.M., Bos J.D., Kapsenberg M.L., de Jong E.C., and Teunissen M.B. Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J Immunol 178 (2007) 1986-1990
45. Dzionek A., Sohma Y., Nagafune J., Cella M., Colonna M., Facchetti F., et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med 194 (2001) 1823-1834
46. Valladeau J., Ravel O., Dezutter-Dambuyant C., Moore K., Kleijmeer M., Liu Y., et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 12 (2000) 71-81
47. Geijtenbeek T.B., Torensma R., van Vliet S.J., van Duijnhoven G.C., Adema G.J., van Kooyk Y., et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 100 (2000) 575-585
48. Goldrath A.W., and Hedrick S.M. Central tolerance matters. Immunity 23 (2005) 113-114
49. + regulatory T cells in human thymus. Nature 436 (2005) 1181-1185
50. Hengartner H., Odermatt B., Schneider R., Schreyer M., Walle G., MacDonald H.R., et al. Delection of self-reative T cells before entry into the thymus medulla. Nature 336 (1988) 388-390
51. Steinman R.M., and Nussenzweig M.C. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 99 (2002) 351-358
52. Rovere P., Sabbadini M.G., Fazzini F., Bondanza A., Zimmermann V.S., Rugarli C., et al. Remnants of suicidal cells fostering systemic autoaggression. Apoptosis in the origin and maintenance of autoimmunity. Arthritis Rheum 43 (2000) 1663-1672
53. de Heer H.J., Hammad H., Soullie T., Hijdra D., Vos N., Willart M.A., et al. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med 200 (2004) 89-98
54. Ochando J.C., Homma C., Yang Y., Hidalgo A., Garin A., Tacke F., et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 7 (2006) 652-662
55. Merad M., Collin M., and Bromberg J. Dendritic cell homeostasis and trafficking in transplantation. Trends Immunol 28 (2007) 353-359
56. Gilliet M., and Liu Y.J. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 195 (2002) 695-704
57. Menges M., Rossner S., Voigtlander C., Schindler H., Kukutsch N.A., Bogdan C., et al. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med 195 (2002) 15-21
58. + T cells. J Immunol 174 (2005) 7433-7439
59. + regulatory T cells restore normoglycemia in diabetic NOD mice. J Exp Med 204 (2007) 191-201
60. Moser M. Dendritic cells in immunity and tolerance-do they display opposite functions?. Immunity 19 (2003) 5-8
61. Battaglia M., Gianfrani C., Gregori S., and Roncarolo M.G. IL-10-producing T regulatory type 1 cells and oral tolerance. Ann NY Acad Sci 1029 (2004) 142-153
62. McGuirk P., McCann C., and Mills K.H. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med 195 (2002) 221-231
63. Manavalan J.S., Rossi P.C., Vlad G., Piazza F., Yarilina A., Cortesini R., et al. High expression of ILT-3 and ILT-4 is a general feature of tolerogenic dendritic cells. Transpl Immunol 11 (2003) 245-258
64. Suciu-Foca N., Manavalan J.S., Scotto L., Kim-Schulze S., Galluzzo S., Naiyer A.J., et al. Molecular characterization of allospecific T suppressor and tolerogenic dendritic cells: review. Int Immunopharmacol 5 (2005) 7-11
65. + T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 199 (2004) 1467-1477
66. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., and Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155 (1995) 1151-1164
67. Kim J.M., Rasmussen J.P., and Rudensky A.Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 8 (2007) 191-197
68. Fujita S., Seino K., Sato K., Sato Y., Eizumi K., Yamashita N., et al. Regulatory dendritic cells act as regulators of acute lethal systemic inflammatory response. Blood 107 (2006) 3656-3664
69. Sato K., Yamashita N., Yamashita N., Baba M., and Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 18 (2003) 367-379
70. Bartz H., Türkel O., Hoffjan S., Rothoeft T., Gonschorek A., and Schauer U. Respiratory syncytial virus decreases the capacity of myeloid dendritic cells to induce interferon-gamma in naïve T cells. Immunology 109 (2003) 49-57
71. Karin M., Lawrence T., and Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124 (2006) 823-835
72. Smith D.E., Renshaw B.R., Ketchem R.R., Kubin M., Garka K.E., and Sims J.E. Four new members expand the interleukin-1 superfamily. J Biol Chem 275 (2000) 1169-1175
73. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23 (2005) 479-490
74. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 87 (1996) 2095-2147
75. Dinarello C.A. Blocking IL-1 in systemic inflammation. J Exp Med 201 (2005) 1355-1359
76. Steinman R.M. Cytokines amplify the function of accessory cells. Immunol Lett 17 (1988) 197-202
77. Pascual V., Allantaz F., Arce E., Punaro M., and Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201 (2005) 1479-1486
78. So A., De Smedt T., Revaz S., and Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9 (2007) R28
79. Larsen C.M., Faulenbach M., Vaag A., Volund A., Ehses J.A., Seifert B., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356 (2007) 1517-1526
80. Ting J.P., Kastner D.L., and Hoffman H.M. CATERPILLERs, pyrin and hereditary immunological disorders. Nat Rev Immunol 6 (2006) 183-195
81. Kishimoto T., Akira S., Narazaki M., and Taga T. Interleukin-6 family of cytokines and gp130. Blood 86 (1995) 1243-1254
82. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6 (2005) 1123-1132
83. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6 (2005) 1133-1141
84. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441 (2006) 235-238
85. Mangan P.R., Harrington L.E., O'Quinn D.B., Helms W.S., Bullard D.C., Elson C.O., et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441 (2006) 231-234
86. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., and Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24 (2006) 179-189
87. Kudo O., Sabokbar A., Pocock A., Itonaga I., Fujikawa Y., and Athanasou N.A. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 32 (2003) 1-7
88. Keul R., Heinrich P.C., Muller-newen G., Muller K., and Woo P. A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine 10 (1998) 729-734
89. Woo P., Wilkinson N., Prieur A.M., Southwood T., Leone V., Livermore P., et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 7 (2005) R1281-R1288
90. Maini R.N., Taylor P.C., Szechinski J., Pavelka K., Broll J., Balint G., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54 (2006) 2817-2829
91. + T cells through IL-12 produced by Listeria-induced macrophages. Science 260 (1993) 547-549
92. Manetti R., Parronchi P., Giudizi M.G., Piccinni M.-P., Maggi E., Trinchieri G., et al. Natural killer cell stimulatory factor [interleukin 12 [IL-12]] induces T helper type 1 [Th1]-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 177 (1993) 1199-1204
93. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3 (2003) 133-146
94. Uhlig H.H., McKenzie B.S., Hue S., Thompson C., Joyce-Shaikh B., Stepankova R., et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 25 (2006) 309-318
95. Kastelein R.A., Hunter C.A., and Cua D.J. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 25 (2007) 221-242
96. Trembleau S., Penna G., Bosi E., Mortara A., Gately M.K., and Adorini L. Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med 181 (1995) 817-821
97. Segal B.M., and Shevach E.M. IL-12 unmasks latent autoimmune disease in resistant mice. J Exp Med 184 (1996) 771-775
98. Mannon P.J., Fuss I.J., Mayer L., Elson C.O., Sandborn W.J., Present D., et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 351 (2004) 2069-2079
99. Cargill M., Schrodi S.J., Chang M., Garcia V.E., Brandon R., Callis K.P., et al. A large-scale genetic association study confirms IL-12B and leads to the identification of IL-23R as psoriasis-risk genes. Am J Hum Genet 80 (2007) 273-290
100. Duerr R.H., Taylor K.D., Brant S.R., Rioux J.D., Silverberg M.S., Daly M.J., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314 (2006) 1461-1463
101. Smits H.H., van Beelen A.J., Hessle C., Westland R., de Jong E., Soeteman E., et al. Commensal Gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 development. Eur J Immunol 34 (2004) 1371-1380
102. Reiner S.L. Development in motion: helper T cells at work. Cell 129 (2007) 33-36
103. Kikly K., Liu L., Na S., and Sedgwick J.D. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol 18 (2006) 670-675
104. Vaknin-Dembinsky A., Balashov K., and Weiner H.L. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol 176 (2006) 7768-7774
105. Lee E., Trepicchio W.L., Oestreicher J.L., Pittman D., Wang F., Chamian F., et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199 (2004) 125-130
106. Schmidt C., Giese T., Ludwig B., Mueller-Molaian I., Marth T., Zeuzem S., et al. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis 11 (2005) 16-23
107. Krueger G.G., Langley R.G., Leonardi C., Yeilding N., Guzzo C., Wang Y., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356 (2007) 580-592
108. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8 (2002) 500-508
109. Matusevicius D., Kivisakk P., He B., Kostulas N., Ozenci V., Fredrikson S., et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 5 (1999) 101-104
110. Chabaud M., Durand J.M., Buchs N., Fossiez F., Page G., Frappart L., et al. Human interleukin-17: a T cell-derived pro-inflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 42 (1999) 963-970
111. Batten M., Li J., Yi S., Kljavin N.M., Danilenko D.M., Lucas S., et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 7 (2006) 929-936
112. Stumhofer J.S., Laurence A., Wilson E.H., Huang E., Tato C.M., Johnson L.M., et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 7 (2006) 937-945
113. Feldmann M., and Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu Rev Immunol 19 (2001) 163-196
114. Victor F.C., Gottlieb A.B., and Menter A. Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin Dermatol 21 (2003) 392-397
115. Nadkarni S., Mauri C., and Ehrenstein M.R. Anti-TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β. J Exp Med 204 (2007) 33-39
116. Palucka A.K., Blanck J.P., Bennett L., Pascual V., and Banchereau J. Cross-regulation of TNF and IFN-α in autoimmune diseases. Proc Natl Acad Sci USA 102 (2005) 3372-3377
117. Hooks J.J., Moutsopoulos H.M., Geis S.A., Stahl N.I., Decker J.L., and Notkins A.L. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 301 (1979) 5-8
118. Ronnblom L.E., Alm G.V., and Oberg K.E. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Int Med 115 (1991) 178-183
119. Bennet L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoieis signatures in Systemic Lupus Erythematosus blood. J Exp Med 2003;197:711-23.
120. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 100 (2003) 2610-2615
121. Crow M.K., and Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res Ther 5 (2003) 279-287
122. Blanco P., Palucka A.K., Gill M., Pascual V., and Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294 (2001) 1540-1543
123. + T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 52 (2005) 201-211
124. Greenberg S.A., Pinkus J.L., Pinkus G.S., Burleson T., Sanoudou D., Tawil R., et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 57 (2005) 664-678
125. Tezak Z., Hoffman E.P., Lutz J.L., Fedczyna T.O., Stephan D., Bremer E.G., et al. Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 168 (2002) 4154-4163
126. Bave U., Nordmark G., Lovgren T., Ronnelid J., Cajander S., Eloranta M.L., et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 52 (2005) 1185-1195
127. Gottenberg J.E., Cagnard N., Lucchesi C., Letourneur F., Mistou S., Lazure T., et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA 103 (2006) 2770-2775
128. Nestle F.O., Conrad C., Tun-Kyi A., Homey B., Gombert M., Boyman O., et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. J Exp Med 202 (2005) 135-143
129. Looney R.J., Anolik J., and Sanz I. New therapies for systemic lupus erythematosus: cellular targets. Rheum Dis Clin North Am 32 (2006) 201-215
130. Le Bon A., Thompson C., Kamphuis E., Durand V., Rossmann C., Kalinke U., et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 176 (2006) 2074-2078
131. Litinskiy M.B., Nardelli B., Hilbert D.M., He B., Schaffer A., Casali P., et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 3 (2002) 822-829
132. Jego G., Palucka A.K., Blanck J.P., Chalouni C., Pascual V., and Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19 (2003) 225-234
133. Means T.K., Latz E., Hayashi F., Murali M.R., Golenbock D.T., and Luster A.D. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 115 (2005) 407-417
134. Bave U., Magnusson M., Eloranta M.L., Perers A., Alm G.V., and Ronnblom L. FcγRIIa is expressed on natural IFN-α-producing cells (plasmacytoid dendritic cells) and is required for the IFN-α production induced by apoptotic cells combined with lupus IgG. J Immunol 171 (2003) 3296-3302
135. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 (2004) 987-995
136. Colonna M. Toll-like receptors and IFN-alpha: partners in autoimmunity. J Clin Invest 116 (2006) 2319-2322
137. Martin D.A., and Elkon K.B. Autoantibodies make a U-turn: the toll hypothesis for autoantibody specificity. J Exp Med 202 (2005) 1465-1469
138. Deane J.A., and Bolland S. Nucleic acid-sensing TLRs as modifiers of autoimmunity. J Immunol 177 (2006) 6573-6578
139. Vollmer J., Tluk S., Schmitz C., Hamm S., Jurk M., Forsbach A., et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves toll-like receptors 7 and 8. J Exp Med 202 (2005) 1575-1585
140. Lang K.S., Recher M., Junt T., Navarini A.A., Harris N.L., Freigang S., et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 11 (2005) 138-145
141. Bave U., Alm G.V., and Ronnblom L. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer. J Immunol 165 (2000) 3519-3526
142. Bave U., Magnusson M., Eloranta M.L., Perers A., Alm G.V., and Ronnblom L. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol 171 (2003) 3296-3302
143. Barrat F.J., Meeker T., Gregorio J., Chan J.H., Uematsu S., Akira S., et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 202 (2005) 1131-1139
144. Christensen S.R., Shupe J., Nickerson K., Kashgarian M., Flavell R.A., and Shlomchik M.J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25 (2006) 417-428
145. Hua J., Kirou K., Lee C., and Crow M.K. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 54 (2006) 1906-1916
146. Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., Beaudette B.C., Shlomchik M.J., and Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416 (2002) 603-607
147. Wu X., and Peng S.L. Toll-like receptor 9 signalling protects against murine lupus. Arthritis Rheum 54 (2006) 336-342
148. Lau C.M., Broughton C., Tabor A.S., Akira S., Flavell R.A., Mamula M.J., et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/toll-like receptor 7 engagement. J Exp Med 202 (2005) 1171-1177
149. Pisitkun P., Deane J.A., Difilippantonio M.J., Tarasenko T., Satterthwaite A.B., and Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312 (2006) 1669-1672
150. Tian J., Avalos A.M., Mao S.Y., Chen B., Senthil K., Wu H., et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8 (2007) 487-496
151. Goldbach-Mansky R., Dailey N.J., Canna S.W., Gelabert A., Jones J., Rubin B.I., et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355 (2006) 581-592
152. Hoffman H.M., Rosengren S., Boyle D.L., Cho J.Y., Nayar J., Mueller J.L., et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364 (2004) 1779-1785
153. Hawkins P.N., Lachmann H.J., Aganna E., and McDermott M.F. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 50 (2004) 607-612
154. Kasper L.H., Everitt D., Leist T.P., Ryan K.A., Mascelli M.A., Johnson K., et al. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. Curr Med Res Opin 22 (2006) 1671-1678
155. Gottlieb A.B., Cooper K.D., McCormick T.S., Toichi E., Everitt D.E., Frederick B., et al. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin 23 (2007) 1081-1092
156. Lovell D.J., Reiff A., Jones O.Y., Schneider R., Nocton J., Stein L.D., et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 54 (2006) 1987-1994
157. Osterman M.T., and Lichtenstein G.R. Current and Future Anti-TNF Therapy for Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 10 (2007) 195-207